RBC Capital Sticks to Its Buy Rating for Dexcom (DXCM)
In a report released on December 17, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Dexcom (DXCM – Research Report), with a ...
Nasdaq3 天
1 Reason to Sell DexCom Stock, and 1 Reason to Buy
Shares of the medical-device maker DexCom (NASDAQ: DXCM) are down by 37% this year. The diabetes-focused healthcare company disappointed investors with its second-quarter results, leading to a ...
Business Insider29 天
Dexcom’s G7 Hospital CGM Poised for Market Breakthrough with NTAP and FDA Approvals
Its products include DexCom G4 PLATINUM System, DexCom G5 Mobil, DexCom G6, and DexCom Share. Read More on DXCM: DexCom NewsMORE Related Stocks Indices Commodities ...
Digital Trends9 天
I tried the Dexcom Stelo, one of the best mobile gadgets for tracking your glucose
Unless you’re an advocate for health tech or a diabetic like me, you may not have heard of Dexcom or Abbott, the two companies that form an oligopoly in the CGM space. Yet, you’re probably ...
Medscape13 年
FDA Approvals
New Continuous Glucose Monitor Software Improves Accuracy The US Food and Drug Administration (FDA) has approved new software for the Dexcom G4 Platinum system that the company says brings its ...
Yahoo Finance4 天
DexCom, Inc. (DXCM)
Two S&P 500 stocks--DexCom and Albemarle--are already on sale for investors to buy in 2025. Dexcom has become the first company to launch a generative AI-powered continuous glucose monitor.